NONYE NELSON: Open Payments
NPI 1003472473 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,709 in 79 payments from 15 companies in 2025. Trend: 2023 $1,356 · 2024 $1,285 · 2025 $1,709
Food & beverage: $1,709
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $489 |
| Novo Nordisk Inc | 17 | $367 |
| AstraZeneca Pharmaceuticals LP | 6 | $234 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $157 |
| Amgen Inc. | 6 | $113 |
| GlaxoSmithKline, LLC. | 3 | $78 |
| Lilly USA, LLC | 4 | $71 |
| PFIZER INC. | 2 | $54 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Viatris Specialty LLC | 1 | $26 |
Products named: VRAYLAR, Ozempic, Kerendia, BREZTRI, OTEZLA, FARXIGA, CREON, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
